Welcome to our dedicated page for Conexeu Sciences SEC filings (Ticker: CNXU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Conexeu Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Conexeu Sciences's regulatory disclosures and financial reporting.
Conexeu Sciences Inc. has a significant shareholder disclosure from Michael G. Wright on a Schedule 13G. Wright reports beneficial ownership of 3,276,643 common shares, representing 12.1% of the company’s common stock. This ownership gives him sole voting and sole dispositive power over all reported shares.
The position includes 750,000 common shares held directly by Wright and 2,148,048 common shares held indirectly through N3GU Investments LLC, a Wyoming limited liability company over which he has sole voting and dispositive power. It also includes 50,000 shares underlying stock options, 78,595 shares underlying warrants, and 250,000 shares underlying performance warrants, each exercisable within 60 days of June 30, 2026. The 12.1% figure is based on 26,758,330 common shares outstanding as of June 10, 2026, plus the exercisable derivative securities held by Wright.
Paisley Capital Holdings Corp reported a significant ownership position in Conexeu Sciences Inc. common stock. As of 06/30/2026, Paisley Capital beneficially owned 1,800,000 shares of Conexeu Sciences Inc. common stock, representing 6.7% of the class.
Paisley Capital, organized in the British Virgin Islands with a principal office in Baar, Switzerland, reported sole voting power and sole dispositive power over all 1,800,000 shares, with no shared voting or dispositive power. The certification section is marked as not applicable, and the filing is signed by Director Jacqueline Elsener on 07/16/2026.
Conexeu Sciences has completed its 12‑month preclinical P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) study for the CXU™ tissue‑restoration platform. In animal models, the study met objectives for facial cheek tissue restoration, a large‑volume 200cc‑equivalent model, and injectable performance benchmarks such as injectability and volumizing behavior.
The company emphasizes that CXU™ and Ten‑Minute Tissue™ remain investigational, with no regulatory clearance or commercial launch. Conexeu plans a predicate‑based 510(k) submission for a lead wound‑care device in Q1 2027, targeting a 90‑day FDA review as a first step before pursuing medical aesthetics and other soft‑tissue indications.
Conexeu Sciences Inc. director Costa Andrew reported holding an option to buy common stock, covering 50,000 underlying shares. The option has an exercise price of $2.30 per share and expires on February 9, 2031.
According to a footnote, these options were granted on February 9, 2026 and vest over 12 months, with 25% vesting at three, six, nine and twelve months from the grant date.
Conexeu Sciences Inc. director Burke April Lynn reported holdings of stock options rather than a new trade. She holds options to buy 50,000 shares of common stock at an exercise price of $2.30 per share, expiring on February 9, 2031. These options were granted on February 9, 2026 and vest in four equal 25% installments over a 12‑month period.
Conexeu Sciences Inc. director Ana Lucia Bastiani-Posner reported her initial holdings of stock options. She holds options to buy 50,000 shares of common stock at an exercise price of $2.30 per share, expiring on February 9, 2031.
The footnote explains these options were granted on February 9, 2026 and vest over 12 months, with 25% of the grant vesting at three, six, nine and twelve months from the grant date. This filing is a baseline disclosure of her derivative equity position rather than a new market transaction.
Conexeu Sciences Inc. director and 10% owner Lynn Sebastian Purcell, through OnePointTwo Capital Ventures LLC, reported significant indirect insider activity in common stock and warrants on 2026-06-18. The LLC bought 202,500 shares of common stock at $0.80 per share, bringing its indirect common stock holdings to 2,734,240 shares. It also exercised warrants for 202,500 underlying common shares at an exercise price of $0.80 and separately bought 202,500 additional warrants at $0.001 per warrant, each exercisable for common stock at $2.30 per share, leaving 625,000 warrants indirectly held.
Conexeu Sciences Inc. ten percent owner Wright Michael G., through N3GU Investments LLC, exercised derivative securities to acquire 250,000 shares of Common Stock at $0.001 per share. Following this transaction, N3GU Investments LLC indirectly holds 2,148,048 Common shares. The Performance Warrants were originally granted for services, totaling 900,000, of which 650,000 have vested; the remaining 250,000 will vest and be exercisable when the company submits a 510(k) application to the U.S. Food and Drug Administration.
Conexeu Sciences Inc. registers 9,481,123 shares of Common Stock via a prospectus supplement to its Form S-1. This supplement incorporates and attaches the Company’s Form 8-K (June 9, 2026) and Form 10-Q (quarter ended April 30, 2026).
The supplement states the Company’s shares trade on Nasdaq under the symbol CNXU and cites a closing price of $9.82 on June 15, 2026. The filing discloses recent warrant activity: issuance and exercises tied to an incentive program and incremental issuances that affected shares outstanding.
Shares outstanding were 26,758,330 as of June 10, 2026. The supplement updates the Prospectus and must be read with the Prospectus for full terms and risk disclosures.
Conexeu Sciences Inc. (CNXU) reported larger losses as it builds out its regenerative medicine platform. For the quarter ended April 30, 2026, the company recorded a net loss of $2,304,283, and a six‑month net loss of $4,023,106, driven mainly by consulting, R&D and management compensation expenses of over $4.1M for the six‑month period.
Total assets were $8,199,679, including cash and cash equivalents of $6,848,064, funded largely through equity financings and a warrant inducement program. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing. Subsequent events include a Nasdaq listing under the symbol CNXU and further warrant exercises.